Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Hematologic Oncology Melanoma & Skin Cancer Biosimilars Brain Cancer Business Management CAR T-cell Therapy COVID-19 Chronic Lymphocytic Leukemia Colorectal Cancer Disparities in Cancer Care Global Oncology Head & Neck Cancers Immuno-Oncology Mantle Cell Lymphoma Multiple Myeloma Myeloproliferative Neoplasms Neoadjuvant HER2+Non-Hodgkin Lymphoma Oncology Nursing News Ovarian Cancer Pediatric Oncology Precision Medicine in Oncology®Prostate Cancer Sarcomas/TGCT Supportive Care Urothelial Cancer

View All >>

Biosimilars
Brain Cancer
Breast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Chronic Lymphocytic Leukemia
Colorectal Cancer
Disparities in Cancer Care
Gastrointestinal Cancer
Genitourinary Cancers
Global Oncology
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Multiple Myeloma
Myeloproliferative Neoplasms
Neoadjuvant HER2+
Non-Hodgkin Lymphoma
Oncology Nursing News
Ovarian Cancer
Pediatric Oncology
Precision Medicine in Oncology®
Prostate Cancer
Sarcomas/TGCT
Supportive Care
Urothelial Cancer

SPOTLIGHT -

OncClub: Join the Chat on Trending Trials in Cancer 2023 nominations are open for Giants of Cancer Care® In-person and virtual events just for HCPs Register | New Options for Advanced HCC

Oncology Societies | Strategic Alliance Partners

home / sap-partner / society

Is your organization missing from this list? Reach out to Noelle Stango, Strategic Alliance Partnership Manager, to learn more about the complimentary strategic partnership program:nstango@mjhlifesciences.com

Society for Immunotherapy of Cancer

Florida Society of Clinical Oncology

Association of Community Cancer Centers

Global Liver Institute

NCODA

Latest Conference Coverage

Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer

Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received

Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022

Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor

View More Latest Conference Coverage